

Received: 18 July 2019 | Revised: 16 August 2019 | Accepted: 2 September 2019

DOI: 10.1111/cea.13500

## ORIGINAL ARTICLE

WILEY

## Clinical Allergy

# Cardiac safety of second-generation H<sub>1</sub>-antihistamines when updosed in chronic spontaneous urticaria

Mauro Cataldi<sup>1</sup>  | Marcus Maurer<sup>2</sup>  | Maurizio Taglialatela<sup>1</sup>  | Martin K. Church<sup>2</sup> 

<sup>1</sup>Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Naples, Italy

<sup>2</sup>Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany

**Correspondence**

Martin K. Church, Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin D-10117, Germany. Email: [mkc@soton.ac.uk](mailto:mkc@soton.ac.uk)

**Abstract**

The symptoms of chronic urticaria, be it chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CindU), are mediated primarily by the actions of histamine on H<sub>1</sub> receptors located on endothelial cells (the weal) and on sensory nerves (neurogenic flare and pruritus). Thus, second-generation H<sub>1</sub> antihistamines (sgAHs) are the primary treatment of these conditions. However, many patients are poorly responsive to licensed doses of antihistamines. In these patients, the current EAACI/GA<sup>2</sup>LEN/EDF/WAO guideline for urticaria suggests up dosing of sgAHs up to fourfold. However, such up dosing is off-label and the responsibility resides with the prescribing physician. Therefore, the safety of the drug when used above its licensed dose is of paramount importance. An important aspect of safety is potential cardiotoxicity. This problem was initially identified some 20 years ago with cardiotoxic deaths occurring with astemizole and terfenadine, two early sgAHs. In this review, we discuss the mechanisms and assessments of potential cardiotoxicity of H<sub>1</sub> antihistamines when up dosed to four times their licensed dose. In particular, we have focused on the potential of H<sub>1</sub> antihistamines to block hERG (human Ether-a-go-go-Related Gene) voltage-gated K<sup>+</sup> channels, also known as Kv11.1 channels according to the IUPHAR classification. Blockade of these channels causes QT prolongation leading to torsades de pointes that may possibly degenerate into ventricular fibrillation and sudden death. We considered in detail bilastine, cetirizine, levocetirizine, ebastine, fexofenadine, loratadine, desloratadine, mizolastine and rupatadine and concluded that all these drugs have an excellent safety profile with no evidence of cardiotoxicity even when up dosed up to four times their standard licensed dose, provided that the prescribers carefully consider and rule out potential risk factors for cardiotoxicity, such as the presence of inherited long QT syndrome, older age, cardiovascular disorders, hypokalemia and hypomagnesemia, or the use of drugs that either have direct QT prolonging effects or inhibit sgAH metabolism.

**KEYWORDS**

cardiovascular safety, long QT syndrome, pharmacology and pharmacogenomics, second generation antihistamines, torsades de points, urticaria

Taglialatela and Church shared last authorship


## 1 | INTRODUCTION

The symptoms of chronic urticaria, be it chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CindU), are mediated primarily by the actions of histamine on  $H_1$  receptors located on endothelial cells (the weal) and on sensory nerves (neurogenic flare and pruritus). The burden of CSU, which is defined as the spontaneous appearance of signs and symptoms of urticaria for more than 6 weeks,<sup>1</sup> is substantial for patients, their family and friends, the healthcare system and society. Continuous treatment with second-generation  $H_1$  antihistamines (sgAHs) is of eminent importance in the treatment of patients with CSU. However, many patients are poorly responsive to licensed doses of antihistamines. In these patients, the current EAACI / GA<sup>2</sup>LEN/EDF/WAO guideline for urticaria suggests up dosing of sgAHs up to fourfold.<sup>1</sup> However, such up dosing is off-label, and consequently, the responsibility resides with the prescribing physician. In this case, the safety of the drug when used above its licensed dose is of paramount importance. This issue is of unquestionable clinical relevance, considering that astemizole and terfenadine, two of the first marketed sgAHs, have been linked to one of the most serious cases of unexpected toxicity after marketing approval: delayed ventricular repolarization (QT interval prolongation) leading to torsade de pointes (TdP) possibly degenerating into ventricular fibrillation and causing sudden death.<sup>2-6</sup>

Over 15 years have lapsed since the cardiotoxicity of sgAHs was reviewed in a consensus paper,<sup>7</sup> which did not, however, specifically address the up dosing issue. Therefore, in this manuscript, we have re-addressed the mechanisms for potential cardiotoxicity of antihistamines, summarized the tests used to investigate this and reviewed the cardiac safety profiles of 9 sgAHs used in the treatment of chronic urticaria. We hope that this will eliminate the nagging doubt about the potential of cardiotoxicity with up dosing with an  $H_1$  antihistamine in the treatment of patients with chronic spontaneous urticaria.

## 2 | MECHANISMS AND ASSESSMENTS OF CARDIOTOXICITY OF $H_1$ ANTIHISTAMINES

The mechanism most frequently involved in cardiotoxicity induced by sgAHs is the blockade of hERG (human Ether-a-go-go-Related Gene, Kv11.1) voltage-gated  $K^+$  channels (Figure 1). These channels contribute to cardiac repolarization by carrying the  $I_{Kr}$  current and, therefore, their blockade causes QT prolongation and ultimately torsade de pointes.<sup>8-13</sup> The molecular determinants for histamine  $H_1$  receptor and hERG channel affinities are completely unrelated for both, first-generation AHs<sup>12</sup> and sgAHs (Figure 1).<sup>9</sup> For most  $H_1$  antihistamines, the plasma concentrations for antihistaminic activity are much lower than those required for hERG channel activation, and only when they are similar is there an enhanced risk of a problem. On this conceptual basis, it has been proposed that the ratio between the hERG  $IC_{50}$  (ie the concentration of drug that causes a 50% decrease in the current carried by hERG channels) and the antihistaminic response  $EC_{50}$  (ie the concentration of drug that causes the 50% of the desired anti-allergic effect) could be used as an indicator of the arrhythmogenic potential of sgAHs, defining a so-called cardiac safety index (CSI).<sup>14</sup> Specific problems arise, however, when trying to define CSI threshold levels below which a drug has to be considered as potentially dangerous. Cavero et al<sup>14</sup> suggested that the CSI threshold should be set at 30, although additional factors contributing to a more complete definition of the risk/benefit ratio for each 2ndGAH should be also taken into account. In support of this view, Redfern and co-workers highlighted that the CSI for the cardiotoxic sgAHs terfenadine and astemizole, calculated as the ratio between hERG  $IC_{50}$  and the effective drug therapeutic plasma concentration (ETPC), was  $< 30$ , while  $> 30$  values are reported for safer sgAHs such as cetirizine, loratadine, mizolastine, ebastine and fexofenadine.<sup>15</sup> Values of CSI  $> 30$  times the threshold are a strong argument in support of the cardiovascular safety of antihistamine up dosing



**FIGURE 1** Diagrammatic representation of the histamine  $H_1$  receptor and the hERG channel in biological membranes. Structurally the binding sites have completely different structures. While  $H_1$  antihistamines have strong binding to histamine  $H_1$  receptors, a different part of the molecule has very weak or negligible binding to the hERG channel. Consequently, potential cardiotoxicity is not a class effect

considering that all drugs belonging to this class have linear and largely predictable pharmacokinetics and that plasma concentrations are roughly expected to increase proportionally when the drug is up dosed. Most sgAHs are tightly bound to plasma proteins and display rather low distribution volumes.<sup>16</sup> Therefore, given that only the free drug fraction is available to interact with hERG channels and that, in most cases, therapeutic drug monitoring does not discriminate between free and bound fractions, it seems reasonable to assume that the drug concentration effectively available to block hERG will be much lower than the total plasma concentration;<sup>16</sup> as a matter of fact, the unbound ETPC was used by Redfern<sup>15</sup> to calculate CSI.

While these considerations predict sgAH up dosing to be generally safe, doctors need to be particularly aware of the risk factors known to precipitate arrhythmic episodes observed at recommended doses of sgAHs; these include concomitant use of QT prolonging drugs and of drugs that can disproportionately increase the plasma concentrations of sgAHs by pharmacokinetic interactions, electrolyte unbalances such as hypokalemia or hypomagnesemia, previous cardiac dysfunction and congenital long QT syndrome.

The identification of hERG as a specific molecular target for drug-induced proarrhythmic effects has led to several attempts to standardize the preclinical assessment of the IC<sub>50</sub> for hERG block, as summarized in the S7B ICH Harmonised Tripartite Guideline on the "Non clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals."<sup>17</sup> This document was then followed and complemented by the ICH E14 Guideline entitled "The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non anti-arrhythmic drugs," defining the characteristic of the so-called thorough QT (TQT) study, which represents the reference protocol for drug proarrhythmic risk assessment for regulatory purposes using a 12-lead ECG recording.<sup>18</sup> Briefly, in a typical TQT study, the QT interval is corrected for heart rate with specific formulas such as the Fridericia's correction; moreover, a positive control represented by a drug unequivocally proven to prolong QTc is always included, and candidate drugs are investigated not only at the recommended therapeutic dose but also at higher doses (usually threefold), a critical issue for our up dosing perspective. The ICH E14 Guideline was first issued in 2004 (thus after the publication of our previous consensus paper<sup>7</sup>). Therefore, no TQT studies were performed with sgAH drugs licensed before that date. At the time of writing, only bilastine, levocetirizine and rupatadine have been investigated in formal TQT studies.<sup>19-22</sup> For all other sgAHs, non-ICH E14 compliant data are available, which, however, often includes doses larger than those recommended.

### 3 | CARDIAC SAFETY OF SGAHs USED AT HIGHER THAN STANDARD DOSES

The next paragraphs summarize relevant preclinical (hERG blockade) and clinical (plasma concentration values, TQT/ conventional ECG

studies) information regarding the cardiovascular safety of specific sgAHs, with special reference to up dosing issues (Table 1).

#### 3.1 | Bilastine

The recommended dose of the benzimidazole-piperidine sgAH bilastine is 20 mg/day.<sup>23,24</sup> This drug has optimal pharmacological properties for up dosing including a high selectivity for H<sub>1</sub> receptors, the lack of a significant CYP450-mediated metabolism and the predicted poor retention in the brain being a good substrate for P-glycoprotein-mediated transport.<sup>25</sup> Importantly, up dosing is also expected not to impact significantly on cardiovascular risk. Indeed, the IC<sub>50</sub> for hERG blockade in vitro is between 6500 and 17 170 nM,<sup>23</sup> whereas C<sub>max</sub> at steady state was about 2-10 times lower in patients treated with single or repeated doses of 20 and 100 mg/day<sup>22</sup> (Table 1). A formal TQT study confirmed the lack of significant effects on cardiac repolarization of bilastine doses five-fold higher than those recommended.<sup>20,22</sup> The clinical evidence accumulated so far confirms the safety of bilastine up dosing in patients with cold urticaria,<sup>26</sup> chronic spontaneous urticaria<sup>27</sup> and pruritus.<sup>28</sup>

#### 3.2 | Cetirizine and levocetirizine

Cetirizine, the carboxylated metabolite of hydroxyzine, is a sgAH of the piperazine family with very low sedating and anticholinergic activities.<sup>29</sup> Cetirizine has a chiral centre and, therefore, exists in two enantiomeric forms, R- and L-cetirizine, of which only L-cetirizine (levocetirizine) is active on H<sub>1</sub> receptors. Levocetirizine has a similar tolerability and a higher potency than the parent racemic form, cetirizine.<sup>30-32</sup>

The recommended daily dose of cetirizine and levocetirizine is 10 and 5 mg/day, respectively.<sup>33,34</sup>

Both cetirizine and levocetirizine have been successfully and safely up dosed for the treatment of cholinergic and chronic spontaneous urticaria.<sup>35-43</sup> Both drugs appear remarkably safe from a cardiovascular point of view, and they are well suited for up dosing. Cetirizine is inactive on hERG channels in concentrations up to 3000 nM in mammalian cells.<sup>44,45</sup> This is higher than the C<sub>max</sub> attained after a single or repeated administration at doses up to threefold higher than the recommended one<sup>30,46</sup> (Table 1). Concerning levocetirizine, no effect on cloned hERG channels was observed in *Xenopus* oocytes at concentrations up to 30 000 nM.<sup>47</sup> This drug reaches peak plasma concentrations of <1000 nM after single or repeated administrations of the recommended 5 mg dose, whereas few data are available on the higher doses (Table 1). Remarkably, however, a C<sub>max</sub> value of about 3000 nM was recorded in volunteers taking a single sixfold higher dose of 30 mg.<sup>21</sup> Collectively, these data argue against a significant blockade of hERG channels in vivo by cetirizine and levocetirizine. In agreement with this, cetirizine did not prolong the QTc interval at doses of up to 60 mg/day (six times the recommended dose) in a non-TQT study performed before the publication of the (ICH) E14 guidance.<sup>48</sup> The safety of levocetirizine

**TABLE 1** Selected pharmacodynamic and pharmacokinetic parameters of the sgAHs mentioned in the text

	hERG IC <sub>50</sub> <sup>a</sup> (nM)	H1 receptor K <sub>i</sub> <sup>b</sup> (nM)	Protein binding (%)		C <sub>max</sub> standard dose (nM)	C <sub>max</sub> Updosing (nM)
BILASTINE	6500-17170 <sup>23</sup>	64 <sup>105</sup>	84-90 <sup>23</sup>	Single dose	490 <sup>106</sup>	Fivefold: 3407 <sup>106</sup>
				Repeated doses	449 <sup>22</sup>	Fivefold: 3041 <sup>22</sup>
CETIRIZINE	No effect up to 3000 <sup>44,45</sup>	47 <sup>107</sup>	93 <sup>33</sup>	Single dose	550 <sup>46</sup>	Threefold: 1740 <sup>46</sup>
				Repeated doses	799 <sup>46</sup>	Threefold: 2140 <sup>46</sup>
DESLORATADINE	1950 <sup>74</sup>	0.9 <sup>107</sup>	82-87 <sup>108</sup>	Single dose	7.0 <sup>76</sup>	Fourfold: 26.0 <sup>76</sup>
				Repeated doses	12.8 <sup>109</sup>	Ninefold: 161.2 <sup>65</sup>
EBASTINE <sup>c</sup>	Ebastine: 300 <sup>51</sup> carebastine: na- possibly inactive (see text)	Ebastine :52 <sup>107</sup> carebastine: 10 <sup>107</sup>	Carebastine: 98 <sup>50</sup>	Single dose	220 <sup>53</sup>	Threefold: 440 <sup>53</sup> Fourfold: 620 <sup>53</sup> Fivefold: 861 <sup>53</sup>
				Repeated doses	260-320 <sup>110</sup>	Twofold: 793 <sup>111</sup>
FEXOFENADINE	214000 <sup>57</sup>	175 <sup>107</sup>	60-80 <sup>112</sup>	Single dose	60 mg: 283 <sup>112</sup> 180 mg: 358 <sup>112</sup>	Threefold (2.7) <sup>c</sup> : 6494 <sup>58</sup> Fourfold (4.4) <sup>c</sup> : 12723 <sup>58</sup>
				Repeated doses	60 mg bid: 596 <sup>112</sup>	Threefold (2.9) <sup>c</sup> : 3124 <sup>58</sup> Eightfold (7.6) <sup>c</sup> : 9323 <sup>58</sup>
LEVOCETIRIZINE	No effect up to 30000 <sup>47</sup>	3 <sup>113</sup>	91-92 <sup>34</sup>	Single dose	586 <sup>21</sup>	Sixfold: 3348 <sup>21</sup>
				Repeated doses	792 <sup>34</sup>	na
LORATADINE	101000 <sup>45</sup> 5150 <sup>74</sup>	138 <sup>107</sup>	97-99 <sup>75</sup>	Single dose	5.5 <sup>75</sup> 12.3 <sup>d75</sup>	Fourfold <sup>d</sup> : 68.3 <sup>75</sup>
				Repeated doses	12.1 <sup>81</sup>	na
MIZOLASTINE	350 <sup>88</sup>	22 <sup>107</sup>	98.4 <sup>114</sup>	Single dose	527 <sup>89</sup>	Fourfold: 2268 <sup>89</sup>
				Repeated doses	539 <sup>89</sup>	Fourfold: 2446 <sup>89</sup>
RUPATADINE	8100 <sup>94</sup>	3.8 <sup>115</sup>	98-99 <sup>115</sup>	Single dose	6.3 <sup>96</sup>	Tenfold: 38.5 <sup>96</sup>
				Repeated doses	7.45 <sup>96</sup>	Tenfold: 552.9 <sup>96</sup>

<sup>a</sup>IC<sub>50</sub> stands for the half maximal inhibitory concentration, that is the concentration of a given drug that causes a 50% inhibition of a specific biological or biochemical activity. In the specific case of sgAHs and hERG activity, it indicates the concentration of the antihistamine drug needed to cause a 50% decrease in the amplitude of the K<sup>+</sup> currents carried by these channels in electrophysiological experiments in vitro.

<sup>b</sup>K<sub>i</sub> is the inhibitory constant and measures the affinity of a certain drug inhibitor for its target; in the specific case reported in this table, it measures the affinity of the indicated sgAHs for H1 receptors in binding experiments in vitro. It is important to mention here that K<sub>i</sub> and binding IC<sub>50</sub> are not identical because the latter but not the former depend on the experimental condition (eg on the concentration of the target protein). For competitive agonists and antagonists, K<sub>i</sub> can be obtained from IC<sub>50</sub> data by using the Cheng and Prusoff equation.<sup>116</sup>

<sup>c</sup>Fexofenadine doses used in ref.<sup>57</sup> are not exact multiples of the therapeutic doses. The closest values to the upscaled doses have been reported, and the exact ratios to therapeutic doses are reported in parentheses.

<sup>d</sup>Data obtained with <sup>14</sup>C-loratadine.

up to 30 mg (sixfold the recommended dose) was demonstrated in a formal TQT study.<sup>21</sup>

### 3.3 | Ebastine

Ebastine is a second-generation piperidine antihistamine structurally related to terfenadine whose recommended dose is 10 mg/day. After being absorbed, ebastine is almost completely converted by CYP2J2 in the liver into the active metabolite carebastine.<sup>49</sup> It is carebastine that is usually measured in plasma for pharmacokinetic studies.<sup>50</sup> In *Xenopus* oocytes, ebastine blocked heterologously expressed hERG channels with a similar affinity (K<sub>d</sub> = 300 vs 400 nM) but with lesser efficacy (46% vs 80%)

than terfenadine.<sup>51</sup> No data are available on the effect of the active metabolite carebastine on recombinant hERG, but Moss and Morganroth<sup>52</sup> mention a personal communication by Roy and Brown stating that, unlike ebastine, this molecule is inactive. Carebastine shows almost linear kinetics with C<sub>max</sub> values linearly related to the dose when single ebastine doses of 10, 30, 40, 50 and 90 mg are used.<sup>53</sup> Data obtained in human studies suggest a good cardiovascular tolerability of ebastine even when up dosed. Indeed, when Moss et al<sup>54</sup> performed a pooled analysis of the ECG findings obtained in the preapproval clinical trials with ebastine, they found no QTc prolongation at the doses of 10 and 20 mg but slight and non-clinically relevant QTc interval increase when given at doses of 60 and 100 mg/day.<sup>55</sup>

### 3.4 | Fexofenadine

Fexofenadine is the active carboxylated metabolite of terfenadine that is generated *in vivo* by CYP3A4-dependent oxidative N-dealkylation.<sup>56</sup> The recommended dose of fexofenadine is 180 mg orally once a day or 60 mg orally 2 times a day. No cardiotoxicity is expected when up dosing fexofenadine because the peak concentrations attained even after the administration of high doses of the drug are more than tenfold lower than the  $IC_{50}$  for human hERG channels (Table 1).<sup>57</sup> More specifically, Russel et al<sup>58</sup> found that the fexofenadine  $C_{max}$  was at least 20 times lower than hERG  $IC_{50}$  after the administration of a single dose of 800 mg (4.4 fold higher than the recommended dose of 180 mg/day) or after the repeated administration of 690 mg twice daily (about 8 fold higher than the recommended dose of 180 mg/day). Pratt et al<sup>59</sup> performed a pooled retrospective analysis of the data on cardiovascular safety collected during the clinical trials with fexofenadine (in doses up to 800 mg once daily or 690 mg twice daily) in healthy subjects and patients with seasonal allergic rhinitis. Overall more than 2100 ECGs and approximately 6000 clinical histories were reviewed with no evidence, respectively, of QT prolongation and cardiac toxicity even at the highest fexofenadine doses.<sup>59</sup> In addition, fexofenadine doses up to 240 and 540 mg/day were used in studies on urticaria in Japan<sup>60</sup> and India,<sup>37</sup> respectively, without any significant unwanted cardiac effect.

### 3.5 | Loratadine and desloratadine

Loratadine is a second-generation piperidine antihistamine drug structurally related to azatadine and cyproheptadine.<sup>61</sup> Loratadine is very well tolerated because it lacks anticholinergic activity and does not cross the blood-brain barrier to cause sedation.<sup>62</sup> After oral administration, this drug undergoes extensive first pass metabolism being converted by CYP3A4 and CYP2D6 to its active metabolite descarboethoxyloratadine (desloratadine), which is about four times more potent at  $H_1$  receptors than loratadine itself.<sup>62,63</sup> Desloratadine has been developed as a drug with clinical indications similar to those of loratadine but with higher potency, longer half-life and lower binding to plasma proteins.<sup>64,65</sup> The recommended doses of loratadine and desloratadine are 10 and 5 mg/day, respectively. Both drugs have been used in several studies at higher than standard doses, including some in patients with urticaria.<sup>36,40,66-72</sup> Up dosing of loratadine and desloratadine to up to fourfold the standard dose does not impose a significant risk of arrhythmias. Loratadine and desloratadine block cloned hERG channels in mammalian cells with much lower potency than terfenadine (330 nM), with estimated  $IC_{50}$  values of about 5000-100000 nM for the former and 1950 nM for the latter.<sup>44,45,73,74</sup> These  $IC_{50}$  values are more than 300 times higher than the maximal plasma concentration attained by loratadine and desloratadine after a single administration of the recommended daily doses of 10 and 5 mg, respectively.<sup>75-77</sup> Importantly,  $C_{max}$  values were more than 100 times lower than hERG  $IC_{50}$  values when loratadine or desloratadine was up dosed twofold or fourfold<sup>75-77</sup> (Table 1). Likewise, during the repeated administration of recommended,

double and fourfold doses of loratadine,  $C_{max}$  was almost a hundred times lower than hERG  $IC_{50}$  at steady state (Table 1).<sup>75</sup> Collectively, these data point to remarkable cardiovascular safety of both loratadine and desloratadine even when up dosed as also confirmed in clinical trials in humans that were performed by a non-TQT approach before the ICH E4 guideline approval. Specifically, no significant effect on cardiac repolarization was observed with loratadine at the recommended dose of 10 mg,<sup>78-81</sup> when given for two weeks at a twofold higher dose,<sup>82</sup> or when used for 13 weeks at a fourfold higher dose.<sup>83</sup> Also, desloratadine did not prolong QTc when given at the recommended 5 mg daily dose<sup>84</sup> or at the dose of 7.5 mg/day.<sup>85,86</sup> No published data are available for higher desloratadine doses with the only exception of an abstract showing the lack of any significant prolongation of QTc after the administration for 10 days at doses ninefold higher than those recommended.<sup>87</sup>

### 3.6 | Mizolastine

The recommended dose of the piperidine sgAH mizolastine is 10 mg. Mizolastine blocks hERG channels with an  $IC_{50}$  of 3400 nM in *Xenopus* oocytes and of 350 nM in mammalian cells.<sup>88</sup> The  $C_{max}$  of mizolastine was 527 nM after the administration of a single 10 mg dose and 2268 nM when a 40 mg single dose was given.<sup>89</sup> At steady state, after the repeated administration of 10 and 40 mg daily doses for 7 days,  $C_{max}$  values, respectively, of 539 and 2446 nM were obtained.<sup>89</sup> Though these values are close to the  $IC_{50}$  for hERG blockade, the free concentration of mizolastine that is actually available to interact with cardiac hERG channels is much lower (around 10 nM) because of the high binding to plasma proteins.<sup>90</sup> The cardiovascular safety of mizolastine in doses higher than those recommended was investigated in two non-TQT studies. In the first of these studies, Chaufour et al.<sup>89</sup> measured the effect on QTc of 10, 20 and 40 mg mizolastine given as single or repeated daily doses for 7 days, without any significant change in ventricular repolarization. Similar results were obtained in the second study, by Delauche-Cavallier et al.,<sup>91</sup> who tested the effect of mizolastine up to 75 mg single dose and 40 mg repeated dose, again without any drug-induced QTc prolongation. Therefore, available evidence suggests that mizolastine can be safely up dosed fourfold without inducing any significant change in cardiac risk.

### 3.7 | Rupatadine

Rupatadine is a sgAH of the piperidine subfamily which differs from other sgAHs in its ability to also block PAF receptors.<sup>92,93</sup> The recommended dosage of rupatadine is 10 mg once a day. Studies *in vitro* showed that rupatadine blocks hERG channels with a  $IC_{50}$  of 8100 nM.<sup>94</sup> As previously reported also, the hERG  $IC_{50}$  of desloratadine, the major metabolite generated by rupatadine *in vivo*, is in the  $\mu$ M range. After oral administration of single or of repeated (five days) standard 10 mg dose doses, rupatadine  $C_{max}$  was always about 2000-fold lower than the aforementioned average  $IC_{50}$  for hERG blockade (Table 1).<sup>95,96</sup> Church and colleagues<sup>2</sup> showed that after a single dose of 40 mg (fourfold higher than the recommended dose),

rupatadine  $C_{max}$  was 36.38 nM, whereas Taubel et al.<sup>96</sup> found values of 38.5 and 552.9 nM in Caucasian subjects receiving 100 mg rupatadine (ten times the recommended dose) as a single or as repeated doses, respectively. An ICH-compliant TQT study showed that rupatadine at a dose of 100 mg, tenfold higher than the recommended dose, did not induce significant changes in cardiac repolarization neither when given as a single dose nor when administered once a day for 5 days.<sup>19</sup> Similar results have recently been reported in Japanese volunteers by Taubel et al.<sup>96</sup> In conclusion, rupatadine updosing does not seem to increase the length of cardiac repolarization to any extent.

## 4 | CONCLUSIONS

As stated in the introduction, the first-line treatment of patients with CSU is the use of standard dosed non-sedating second-generation  $H_1$  antihistamines.<sup>1</sup> However, many patients with CSU do not show complete control of their disease with standard doses.<sup>97</sup> In these patients, up dosing of up to fourfold higher than standard doses of their  $H_1$  antihistamine is recommended by the current EAACI/GA<sup>2</sup>LEN/EDF/WAO guideline for urticaria.<sup>1</sup> Several studies have confirmed that treatment of CSU by higher than standard doses of  $H_1$  antihistamine, that is up dosing of an sgAH, is more effective than treatment with the standard dose for most sgAHs.<sup>27,36,38,72,98,99</sup> No cardiotoxicity was reported in any of these studies. In contrast to up dosing, one study has shown that the use of a combination of  $H_1$  antihistamines each at their licensed dose is less effective than up dosing with a single antihistamine.<sup>100</sup> The authors suggest that the reason for this is unknown interactions and addition of side-effects in the combination therapy.

Despite the clear guidelines and the overwhelming evidence of the clinical benefit of up dosing, a recent survey of 528 patients with uncontrolled CSU and who were eligible for treatment escalation showed that only 3% received up dosing of  $H_1$  antihistamines.<sup>101</sup> The reasons for this are not well understood but are held to include that up dosing is off-label and perceived to be linked to reduced cardiac safety.

Our present review clearly shows that sgAHs, at up to fourfold their standard dose, have excellent cardiac safety profiles, although there are differences in the quality of the supporting evidence for the safety of the different drugs. However, lower quality evidence does not mean lower cardiac safety. A review by Ołasińska-Wiśniewska<sup>102</sup> supports our findings and concludes that such phenomena are potentially manifested only in the cases of high overdose far beyond the suggested therapeutic levels. A potential limitation of our study, however, is that the data that we reviewed were mainly obtained either in studies in vitro or in healthy volunteers. Therefore, we cannot exclude that some difference could exist in patients affected with chronic urticaria. Furthermore, there are certain groups of patients, especially the ones with inherited long QT syndrome, the elderly (ie according to WHO definitions, people older than 65 years<sup>103</sup>) and

patients with cardiovascular diseases, who require special attention. These patients should be warned not to overdose their prescribed antihistamines and not to combine them with drugs such as antifungal drugs and macrolides, or food and beverages, such as grapefruit juice, that inhibit their metabolism by CYPs (mainly but not exclusively CYP3A4), nor with any drugs that prolong QT intervals, such as anti-arrhythmics, antimicrobials, tricyclic antidepressants, neuroleptics and prokinetics. A special caution is also advised in the presence of electrolyte unbalances such as hypokalemia and hypomagnesemia, and it should be remembered that these conditions can be precipitated by proton pumps inhibitors, drugs that, in clinical practice, are usually considered harmless.<sup>104</sup>

Our conclusion is that the sgAHs discussed in this review, namely bilastine, cetirizine, levocetirizine, ebastine, fexofenadine, loratadine, desloratadine, mizolastine and rupatadine, all have an excellent safety profile with no evidence of cardiotoxicity even at up to four times their standard licensed dose.

## CONFLICT OF INTEREST

Mauro Cataldi has no conflict of interest to disclose. Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Aralez, Genentech, GSK, Menarini, Merckle Recordati, Moxie, Novartis, Sanofi, MSD and Uriach. Maurizio Tagliatalata has no conflict of interest to disclose. Martin Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi-Aventis and Uriach.

## ORCID

Mauro Cataldi  <https://orcid.org/0000-0001-7787-3406>

Marcus Maurer  <https://orcid.org/0000-0002-4121-481X>

Maurizio Tagliatalata  <https://orcid.org/0000-0002-8202-0560>

Martin K. Church  <https://orcid.org/0000-0002-1639-9410>

## REFERENCES

1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy*. 2018;73(7):1393-1414.
2. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. *Allergy*. 2010;65(4):459-466.
3. Clark S. Dangers of non-sedating antihistamines. *Lancet*. 1997;349(9061):1268.
4. de Abajo FJ, Rodriguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. *Br J Clin Pharmacol*. 1999;47(3):307-313.
5. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. *Lancet*. 1997;349(9061):1322.
6. Leurs R, Church MK, Tagliatalata M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. *Clin Exp Allergy*. 2002;32(4):489-498.



7. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. *Clin Exp Allergy*. 2003;33(9):1305-1324.
8. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. *Circulation*. 1996;94(4):817-823.
9. Soldovieri MV, Miceli F, Tagliatalata M. Cardiotoxic effects of antihistamines: from basics to clinics (...and back). *Chem Res Toxicol*. 2008;21(5):997-1004.
10. Tagliatalata M, Castaldo P, Pannaccione A, Giorgio G, Annunziato L. Human ether-a-gogo related gene (HERG) K<sup>+</sup> channels as pharmacological targets: present and future implications. *Biochem Pharmacol*. 1998;55(11):1741-1746.
11. Tagliatalata M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. *Clin Exp Allergy*. 1999;29(Suppl 3):182-189.
12. Tagliatalata M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. *Trends Pharmacol Sci*. 2000;21(2):52-56.
13. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in *Xenopus* oocytes by the histamine receptor antagonists terfenadine and astemizole. *FEBS Lett*. 1996;385(1-2):77-80.
14. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. *Expert Opin Pharmacother*. 2000;1(5):947-973.
15. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. *Cardiovasc Res*. 2003;58(1):32-45.
16. Church DS, Church MK. Pharmacology of antihistamines. *World Allergy Organ J*. 2011;4(3 Suppl):S22-S27.
17. Anonymous. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B. 2005. [https://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Safety/S7B/Step4/S7B\\_Guideline.pdf](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf). Accessed May 5, 2019.
18. Anonymous. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs E14. 2005. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use.
19. Donado E, Izquierdo I, Perez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. *Br J Clin Pharmacol*. 2010;69(4):401-410.
20. Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. *Clin Drug Investig*. 2012;32(5):339-351.
21. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. *Eur J Clin Pharmacol*. 2007;63(11):1011-1017.
22. Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. *J Clin Pharmacol*. 2012;52(6):893-903.
23. Anonymous. Product monograph including patient medication information PrBLEXTEN™ (Bilastine). 2016. <https://aralez.com/wp-content/uploads/2016/12/BLEXTEN-Product-Monography-Englis.pdf>. Accessed May 15, 2019.
24. Carter NJ. Bilastine: in allergic rhinitis and urticaria. *Drugs*. 2012;72(9):1257-1269.
25. Church MK, Labeaga L. Bilastine: a new H1 -antihistamine with an optimal profile for up dosing in urticaria. *J Eur Acad Dermatol Venereol*. 2017;31(9):1447-1452.
26. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. *Allergy*. 2013;68(7):921-928.
27. Weller K, Church MK, Hawro T, et al. Up dosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: a real-life study. *Allergy*. 2018;73(10):2073-2075.
28. Serra E, Campo C, Novak Z, et al. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. *J Dermatolog Treat*. 2019. <https://doi.org/10.1080/09546634.2019.1590522>
29. Sheffer AL, Samuels LL. Cetirizine: antiallergic therapy beyond traditional H1 antihistamines. *J Allergy Clin Immunol*. 1990;86(6 Pt 2):1040-1046.
30. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. *Drugs*. 2004;64(5):523-561.
31. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. *Drugs*. 2006;66(7):973-996.
32. Tillement JP, Testa B, Bree F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. *Biochem Pharmacol*. 2003;66(7):1123-1126.
33. Anonymous. Zyrtec® FDA Label 2002. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2002/19835s15\\_20346s8lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19835s15_20346s8lbl.pdf). Accessed April 30, 2019.
34. Anonymous. Xyzal® (levocetirizine dihydrochloride) FDA Label. 2008. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/022064s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022064s009lbl.pdf). Accessed April 30, 2019.
35. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. *Clin Exp Dermatol*. 2007;32(1):34-38.
36. Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Up dosing non-sedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. *Br J Dermatol*. 2016;175(6):1153-1165.
37. Godse KV. Up dosing of antihistamines to improve control of chronic urticaria. *Indian J Dermatol Venereol Leprol*. 2010;76(1):61-62.
38. Koch K, Weller K, Werner A, Maurer M, Altrichter S. Antihistamine up dosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. *J Allergy Clin Immunol*. 2016;138(5):1483-1485. e1489.
39. Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. *J Dermatolog Treat*. 2017;28(6):539-543.
40. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. *J Allergy Clin Immunol*. 2010;125(3):676-682.
41. Tharp MD. Cetirizine: a new therapeutic alternative for chronic urticaria. *Cutis*. 1996;58(1):94-98.
42. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. *Acta Derm Venereol*. 1995;75(2):147-149.

43. Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. *Dermatology*. 1996;193(4):324-327.
44. Davie C, Pierre-Valentin J, Pollard C, et al. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. *J Cardiovasc Electrophysiol*. 2004;15(11):1302-1309.
45. Tagliatalata M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K<sup>+</sup> channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. *Mol Pharmacol*. 1998;54(1):113-121.
46. Sasa MNM, Kojima T. Pharmacokinetics of single and multiple doses of a new antiallergic drug, cetirizine, and examination of its safety. *Jpn J Clin Pharmacol Ther*. 1995;26:509-522.
47. Anonymous. Center for drug evaluation and research. Application number 22-157. Pharmacology Reviews. 2007. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2008/022157s000PharmR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022157s000PharmR.pdf). Accessed May 8, 2019.
48. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. *Clin Pharmacol Ther*. 1994;56(3):295-301.
49. Liu KH, Kim MG, Lee DJ, et al. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. *Drug Metab Dispos*. 2006;34(11):1793-1797.
50. Wiseman LR, Faulds D. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. *Drugs*. 1996;51(2):260-277.
51. Ko CM, Ducic I, Fan J, Shuba YM, Morad M. Suppression of mammalian K<sup>+</sup> channel family by ebastine. *J Pharmacol Exp Ther*. 1997;281(1):233-244.
52. Moss AJ, Morganroth J. Cardiac effects of ebastine and other antihistamines in humans. *Drug Saf*. 1999;21(Suppl 1):69-80; discussion 81-67.
53. Martínez-Tobed ATE, Segura J, Roberts DJ. Pharmacokinetic studies of ebastine in rats, dogs and man. *Drugs Today*. 1992;28(Suppl. B):57-67.
54. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. *Clin Exp Allergy*. 1999;29(Suppl 3):200-205.
55. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. *Br J Clin Pharmacol*. 2001;52(2):201-204.
56. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. *Drug Metab Dispos*. 1993;21(3):403-409.
57. Rampe D, Wible B, Brown AM, Dage RC. Effects of terfenadine and its metabolites on a delayed rectifier K<sup>+</sup> channel cloned from human heart. *Mol Pharmacol*. 1993;44(6):1240-1245.
58. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. *Clin Pharmacol Ther*. 1998;64(6):612-621.
59. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. *Clin Exp Allergy*. 1999;29(Suppl 3):212-216.
60. Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. *J Dermatolog Treat*. 2013;24(6):477-480.
61. Clissold SP, Sorkin EM, Goa KL. Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. *Drugs*. 1989;37(1):42-57.
62. Barenholtz HA, McLeod DC. Loratadine: a non-sedating antihistamine with once-daily dosing. *DICP*. 1989;23(6):445-450.
63. Zhang YF, Chen XY, Zhong DF, Dong YM. Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. *Acta Pharmacol Sin*. 2003;24(7):715-718.
64. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. *Drug Saf*. 2005;28(12):1101-1118.
65. Henz BM. The pharmacologic profile of desloratadine: a review. *Allergy*. 2001;56(Suppl 65):7-13.
66. Bruttman G, Pedrali P. Loratadine (SCH29851) 40 mg once daily versus terfenadine 60 mg twice daily in the treatment of seasonal allergic rhinitis. *J Int Med Res*. 1987;15(2):63-70.
67. Choonhakarn C, Chaowattanapanit S, Julianon N. The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. *Int J Dermatol*. 2018;57(4):423-427.
68. Godse K, Bhattar P, Patil S, Nadkarni N, Gautam M. Updosing of Nonsedating Anti-histamines in Recalcitrant Chronic Urticaria. *Indian J Dermatol*. 2016;61(3):273-278.
69. Gutkowski A, Bedard P, Del Carpio J, et al. Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol*. 1988;81(5 Pt 1):902-907.
70. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with non-sedating antihistamines: is there evidence for updosing? *J Investig Allergol Clin Immunol*. 2013;23(3):141-144; quiz 142 p preceding 145.
71. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. *J Allergy Clin Immunol*. 2009;123(3):672-679.
72. Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects—a retrospective survey study. *PLoS ONE*. 2011;6(9):e23931.
73. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. *J Pharmacol Exp Ther*. 2006;316(3):1098-1106.
74. Wisniewska B, Lisowski B, Kulig M, Polak S. Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. *J Appl Toxicol*. 2018;38(4):450-458.
75. Anonymous. Product monograph CLARITIN® 2019. <https://www.bayer.ca/omr/online/claritin-pm-en.pdf>. Accessed May 18, 2019.
76. Gupta S, Banfield C, Affrime M, et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. *Clin Pharmacokinet*. 2002;41(Suppl 1):1-6.
77. Hilbert J, Radwanski E, Weglein R, et al. Pharmacokinetics and dose proportionality of loratadine. *J Clin Pharmacol*. 1987;27(9):694-698.
78. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. *Clin Pharmacol Ther*. 1995;58(3):269-278.
79. Carr RA, Edmonds A, Shi H, et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. *Antimicrob Agents Chemother*. 1998;42(5):1176-1180.
80. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. *Br J Clin Pharmacol*. 2005;59(3):346-354.
81. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant



- administration of ketoconazole or cimetidine. *Br J Clin Pharmacol*. 2000;50(6):581-589.
82. Abernethy DR, Barbey JT, Franc J, et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. *Clin Pharmacol Ther*. 2001;69(3):96-103.
  83. Afrime MBM, Lorber RR, Danzig MR, Cuss F. A 3-month evaluation of electrocardiographic effects of loratadine in healthy individuals. *Advances in Therapy*. 1999;16(4):149-157.
  84. Simons FE, Prenner BM, Finn A, Jr., Desloratadine Study G. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. *J Allergy Clin Immunol*. 2003;111(3):617-622.
  85. Banfield C, Herron J, Keung A, Padhi D, Afrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. *Clin Pharmacokinet*. 2002;41(Suppl 1):37-44.
  86. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Afrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. *Clin Pharmacokinet*. 2002;41(Suppl 1):29-35.
  87. Banfield CPD, Glue P, Herron JM, Statkevich P, Afrime MB. Electrocardiographic effects of multiple high doses of desloratadine-abstracts of the AAAAI 56th annual meeting 03 March 2000 - 08 March 2000; abstract 1119. *J Allergy Clin Immunol* 2000;2(1 Part 2):S383.
  88. Tagliatala M, Pannaccione A, Castaldo P, Giorgio G, Annunziato L. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. *Br J Pharmacol*. 2000;131(6):1081-1088.
  89. Chaufour S, Caplain H, Lilienthal N, et al. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. *Br J Clin Pharmacol*. 1999;47(5):515-520.
  90. De Bruin ML, Petterson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. *Eur Heart J*. 2005;26(6):590-597.
  91. Delauche-Cavallier MC, Chaufour S, Guerauld E, Lacroux A, Murrieta M, Wajman A. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. *Clin Exp Allergy*. 1999;29(Suppl 3):206-211.
  92. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. *Drugs*. 2007;67(3):457-474.
  93. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). *J Pharmacol Exp Ther*. 1997;280(1):114-121.
  94. Anonymus. Australian Public Assessment Report for Rupatadine. 2011. <https://www.tga.gov.au/sites/default/files/auspar-rupafin.pdf>. Accessed May 2, 2019.
  95. Anonymus. Rupatadine 10 mg Tablets. Summary of Product Characteristics (smpc). <https://www.medicines.org.uk/emc/product/2501/smpc>. 2019. Accessed May 2, 2019.
  96. Taubel J, Ferber G, Fernandes S, Santamaria E, Izquierdo I. Cardiac safety of rupatadine in a single-ascending-dose and multiple-ascending-dose study in healthy Japanese subjects, using intensive electrocardiogram assessments-comparison with the previous white Caucasian thorough QT study. *Clin Pharmacol Drug Dev*. 2018;7(1):67-76.
  97. Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study. *Clin Exp Allergy*. 2017;47(5):684-692.
  98. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. *Br J Dermatol*. 2012;166(5):1095-1099.
  99. Weller K, Maurer M. Antihistamine up dosing in chronic urticaria - is there enough evidence? *Br J Dermatol*. 2016;175(6):1134-1135.
  100. Schultz S, Metz M, Siepmann D, Luger TA, Maurer M, Stander S. Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series. *Hautarzt*. 2009;60(7):564-568.
  101. Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. *Clin Exp Allergy*. 2019;49(5):655-662.
  102. Olasinska-Wisniewska A, Olasinski J, Grajek S. Cardiovascular safety of antihistamines. *Postepy Dermatol Alergol*. 2014;31(3):182-186.
  103. World Health Organization. Men Ageing And Health. Achieving health across the life span. 1999. [https://apps.who.int/iris/bitstream/handle/10665/66941/WHO\\_NMH\\_NPH\\_01.2.pdf;jsessionid=85677462D8AEF95AE4FBB4E336D53FDD?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/66941/WHO_NMH_NPH_01.2.pdf;jsessionid=85677462D8AEF95AE4FBB4E336D53FDD?sequence=1). Accessed August 12, 2019.
  104. Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. *Expert Opin Drug Saf*. 2013;12(5):709-716.
  105. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. *Drugs R D*. 2005;6(6):371-384.
  106. Crean CS, Roupe KR, Sologuren A, Valiente R. The pharmacokinetics of bilastine after single and 14 days once daily administration (P252). *Basic Clin Pharmacol Toxicol*. 2007;101(Suppl. 1):148.
  107. Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. *Eur J Pharmacol*. 2002;449(3):229-237.
  108. Anonymus. Clarinex full prescribing information. 2014.
  109. Afrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. *Clin Pharmacokinet*. 2002;41(Suppl 1):13-19.
  110. Anonymus. EBASTINE SANDOZ 10 mg, comprimé orodispersible - Résumé des caractéristiques du produit. 2019.
  111. Yamaguchi T, Hashizume T, Matsuda M, et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. *Arzneimittelforschung*. 1994;44(1):59-64.
  112. Anonymus. ALLEGRA® (fexofenadine hydrochloride) Prescribing Information. 2003. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2003/20786se8-014,20872se8-011,20625se8-012\\_allegra\\_lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20786se8-014,20872se8-011,20625se8-012_allegra_lbl.pdf). Accessed May 6, 2019.
  113. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). *Mol Pharmacol*. 2002;61(2):391-399.
  114. Anonymus. Mizollen 10 mg modified-release tablets Summary of Product Characteristics (smpc). 2019. <https://www.medicines.org.uk/emc/product/363/smpc>. Accessed May 6, 2019.
  115. Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. *Allergo J Int*. 2014;23(3):87-95.
  116. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. *Biochem Pharmacol*. 1973;22(23):3099-3108.

**How to cite this article:** Cataldi M, Maurer M, Tagliatala M, Church MK. Cardiac safety of second-generation H<sub>1</sub>-antihistamines when up dosed in chronic spontaneous urticaria. *Clin Exp Allergy*. 2019;00:1-9. <https://doi.org/10.1111/cea.13500>